FluLaval Quadrivalent Vaccine Approved

FLULAVAL QUADRIVALENT (influenza virus) vaccine
FLULAVAL QUADRIVALENT (influenza virus) vaccine
The FDA has approved FluLaval Quadrivalent, GlaxoSmithKline's second quadrivalent intramuscular influenza vaccine indicated in patients >3 years of age.

GlaxoSmithKline announced that the FDA has approved FluLaval Quadrivalent (influenza virus vaccine) for the active immunization of patients >3 years of age to help prevent disease caused by seasonal influenza virus subtypes A and B. This four-strain influenza vaccine contains two A virus and two B virus strains, which help broaden coverage.

RELATED: Immunization Resource Center

FluLaval Quadrivalent is the second intramuscular quadrivalent vaccine approved by the FDA. Fluarix Quadrivalent was first approved by the FDA in December 2012 and is already being shipped to customers. The former FluLaval Trivalent vaccine was limited for use in patients >18 years of age, but now both quadrivalent vaccines are approved for use in children >3 years of age as well as for adults.

FluLaval Quadrivalent will be available in multi-dose vials, while Fluarix Quadrivalent is available in 0.5mL pre-filled syringes. GlaxoSmithKline anticipates a limited availability of FluLaval Quadrivalent this influenza season, and will immediately begin taking orders on GSKVaccinesDirect.com.

For more information call (888) 825-5249 or visit GSK.com.